GenVec Inc

GenVec — Shareholder Meeting (June 2011)

21 slides from GenVec's shareholder meeting presentation, Jun 17, 2011

  1. Slide 1: 2011 Annual Stockholders Meeting

    2011 Annual Stockholders Meeng

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements herein relang to future financial or business performance, condions or strategies and other financial and business maers, including expectaons regarding future revenues and operang expenses, are forward-looking statements within the meaning of the Private Securies Li

  3. Slide 3: Key Points

    Key Points • Stock price – Gap between price and intrinsic value – Execute on the business plan – Educate invesng community • Business model • Upcoming milestones June 15, 2011 Annual Stockholders Meeng 3

  4. Slide 4: GenVec Strategy

    GenVec Strategy Build shareholder value by Using differenated, proprietary technology to create superior therapeucs and vaccines that are developed and commercialized through collaboraons June 15, 2011 Annual Stockholders Meeng 4

  5. Slide 5: Collaborations Drive Development

    Collaboraons Drive Development Human Therapeucs Human Vaccines Animal Health An Array of Product Programs Generated by GenVec’s Proprietary, Core Technology June 15, 2011 Annual Stockholders Meeng 5

  6. Slide 6: A True Platform

    A True Plaorm • Flexible, cost-effecve product discovery – Enables therapeucs and vaccines – Genes used to produce desired proteins – Rapid proof of concept tesng • Product candidates that meet partner’s needs – Address crical problems – Proprietary • Manufacturing, stability and safety advantages J

  7. Slide 7: GenVec Programs

    GenVec Programs Human Vaccines Human Therapeucs Animal Health • RSV (NIH) • Hearing Loss & • FMD • Dengue Fever (NMRC Balance Disorders ─ Development & HJF) (Novars) (DHS) • Malaria (USMMVP) • TNFerade for Cancer ─ Commercial • HIV (NIH – VRC) (Merial) • HSV-2 • Swine diseases (Merial) June 15, 2011

  8. Slide 8: Recent Progress

    Recent Progress • Hearing loss: Manufacturing of clinical supplies • Dengue fever: New collaboraon and funding • RSV: Partnering efforts iniated • FMD: Commercializaon agreement with Merial • Viral diseases of swine: New Merial agreement June 15, 2011 Annual Stockholders Meeng 8

  9. Slide 9: Key Objectives

    Key Objecves Vaccines Therapeucs Animal Health • RSV: Corporate • Advance hearing loss to • FMD: Field safety study collaboraon the clinic (Novars) (DHS) • Dengue fever: Animal • Collaboraon to develop • FMD: Animal tesng data (NMRC) TNFerade (Merial) • Malaria: Lead • Swine diseases: Iniate opmizao

  10. Slide 10: Financial Highlights: Benefits of Collaborations

    Financial Highlights Benefits of Collaboraons 2010 2011(proj) Revenues $16.5M $20-22M Cash Burn $10.7M $6-8M Cash (12/31) $35.2M $27-29M June 15, 2011 Annual Stockholders Meeng 10

  11. Slide 11: Hearing Loss and Balance Disorders

    HEARING LOSS AND BALANCE DISORDERS

  12. Slide 12: Overview

    Overview • 30- 40 million Americans could benefit from a mechanical device to assist hearing • Our innovave approach is first in class in a major commercial opportunity • Our collaborator, Novars, is a global leader in novel therapeucs • The lead candidate is advancing to the clinic June 15, 2011 An

  13. Slide 13: Novartis Collaboration

    Novars Collaboraon • Novars responsible for worldwide development and commercializaon • Up to $213.6M in milestone payments • Royales on product sales • Addional $12.7M development agreement for supply of clinical materials June 15, 2011 Annual Stockholders Meeng 13

  14. Slide 14: The Ear

    The Ear June 15, 2011 Annual Stockholders Meeng 14

  15. Slide 15: The Problem: Loss of Sensory Cells

    The Problem: Loss of Sensory Cells • Trauma causes loss of sensory cells • Loss of cells causes loss of hearing Mild Loss • Mammals cannot regenerate sensory cells Severe Loss June 15, 2011 Annual Stockholders Meeng 15

  16. Slide 16: Therapeutic Strategy: Generate New Sensory Cells

    Therapeuc Strategy: Generate New Sensory Cells • Convert supporng cells to needed sensory cells • Trigger conversion with the natural developmental regulator - Atonal protein • Deliver the Atonal gene to the supporng cells using an adenovector to produce the protein • Atonal protein induces sensory

  17. Slide 17: Regeneration of Hair Cells

    Regeneraon of Hair Cells Untreated Treated Izumikawa et al. Nature Medicine, 2005, 11(3): 271-276 June 15, 2011 Annual Stockholders Meeng 17

  18. Slide 18: Regenerated Sensory Cells Attract Nerves

    Regenerated Sensory Cells Aract Nerves Neuronal outgrowth New sensory cell Kawamoto et al. J. Neuroscience, 2003, 23(11): 4395-4400 June 15, 2011 Annual Stockholders Meeng 18

  19. Slide 19: Treatment Restores Hearing

    Treatment Restores Hearing Deafened Treated Guinea Pig Model Control ABR Threshold (dB SPL) 105 90 75 60 45 30 15 4 8 16 24 Frequency (kHz) Izumikawa et al. Nature Medicine, 2005, 11(3): 271-276 June 15, 2011 Annual Stockholders Meeng 19

  20. Slide 20: Differentiated Vaccines

    Differenated Vaccines • Broadly applicable vaccine technology – Suite of vectors for gene delivery – Versale cell lines for vector producon – Smulaon of both arms of immune system • Vaccines that overcome known problems – Respiratory Syncyal Virus (RSV) – Foot and mouth disease (FMD) – Herpes simple

  21. Slide 21: In Summary

    In Summary • Sustainable business strategy • Funded product pipeline with many upcoming development milestones • Emerging partnering opportunies • Solid financial posion: Greater than 3 years of operang capital June 15, 2011 Annual Stockholders Meeng 21

Genvec — Shareholder Meeting (June 2011) on 6ix